A drug used to treat advanced renal cell carcinoma (a type of kidney cancer) that was treated with antiangiogenesis therapy. Nivolumab is also used alone or with ipilimumab to treat melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used with ipilimumab in patients whose cancer does not have a certain BRAF gene mutation. It is used alone in patients whose disease got worse after being treated with ipilimumab and who may have also been treated with a BRAF inhibitor. Nivolumab is also used to treat non-small cell lung cancer that has spread to other parts of the body. It is used in patients whose disease got worse during or after treatment with anticancer drugs that included platinum and who may have also been treated with other anticancer therapy. It is also being studied in the treatment of other types of cancer. Nivolumab binds to a substance called PD-1, which is found on T cells (a type of white blood cell). Nivolumab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Opdivo.